Press Releases.

Completed Preparations and Request for FDA Meeting to Obtain Feedback on Approach to Addressing Remaining Hold Requirements

--Company also Announces Participation in a Panel Discussion at the 2021 Wedbush PacGrow Healthcare Conference

Study demonstrates clinical proof of mechanism with statistically significant increases in polycystin levels following RGLS4326 treatment in the first cohort of patients with ADPKD

Data to Be Presented Today at the Oppenheimer Rare & Orphan Disease Summit

Regulus Therapeutics Demonstrates Target Engagement in First-Ever Study of RGLS4326 in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Demonstrated Pharmacokinetic Profile Similar to Healthy Volunteers